Lista de obras - Jeffrey Yap - Dominio Público Uruguay

A general method to correct PET data for tissue metabolites using a dual-scan approach.

artículo científico publicado en 2000

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer

artículo científico publicado en 2014

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression

artículo científico publicado en 2012

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

artículo científico publicado en 2003

Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET

artículo científico publicado en 1999

Bevacizumab plus ipilimumab in patients with metastatic melanoma

artículo científico publicado en 2014

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool

artículo científico publicado en 2010

Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning

artículo científico publicado en 2011

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

artículo científico publicado en 2008

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal c

artículo científico publicado en 2011

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

artículo científico publicado en 2006

Considerations for the use of imaging tools for phase II treatment trials in oncology

artículo científico publicado en 2009

Correlation of Glioma Proliferation and Hypoxia by Luciferase, Magnetic Resonance, and Positron Emission Tomography Imaging

artículo científico publicado en 2018

Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma

artículo científico publicado en 2016

Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial ⬇️

artículo científico publicado el 21 de mayo de 2012

Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.

artículo científico publicado en 2012

Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial

scientific article published on 01 August 2009

F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.

artículo científico publicado en 2008

FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma

artículo científico publicado en 2015

Four-Dimensional Positron Emission Tomography: Implications for Dose Painting of High-Uptake Regions ⬇️

artículo científico publicado el 13 de octubre de 2010

Image-guided cancer therapy using PET/CT.

artículo científico publicado en 2004

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

artículo científico publicado en 2013

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

artículo científico publicado en 2016

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

artículo científico publicado en 2014

Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action

artículo científico publicado en 2000

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

artículo científico publicado en 2009

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy

artículo científico publicado en 2010

On-line measurement of exhaled [11C]CO2 during PET

artículo científico publicado en 2000

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomogr

artículo científico publicado en 2015

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

artículo científico publicado en 2019

Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody

artículo científico publicado en 2006

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

artículo científico publicado en 2012

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

artículo científico publicado en 2014

Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials

artículo científico publicado en 2015

The influential role of BCL2 family members in synovial sarcomagenesis.

artículo científico publicado en 2017

Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology

artículo científico publicado en 2014

Lista de obras de Jeffrey Yap

A general method to correct PET data for tissue metabolites using a dual-scan approach.

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET

Bevacizumab plus ipilimumab in patients with metastatic melanoma

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool

Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal c

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Considerations for the use of imaging tools for phase II treatment trials in oncology

Correlation of Glioma Proliferation and Hypoxia by Luciferase, Magnetic Resonance, and Positron Emission Tomography Imaging

Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma

Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial ⬇️

Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.

Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial

F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.

FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma

Four-Dimensional Positron Emission Tomography: Implications for Dose Painting of High-Uptake Regions ⬇️

Image-guided cancer therapy using PET/CT.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy

On-line measurement of exhaled [11C]CO2 during PET

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomogr

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials

The influential role of BCL2 family members in synovial sarcomagenesis.

Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology